Citi raised the firm’s price target on Editas Medicine to $16 from $11 and keeps a Buy rating on the shares post the Q4 report. Editas reached alignment with FDA that the ongoing RUBY trial will serve as a single Phase 1/2/3 trial sufficient to support a potential filing for reni-cel in sickle cell disease, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
- Is EDIT a Buy, Before Earnings?
- Editas Medicine highlights 2024 anticipated milestones, strategic priorities
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
